Better Buy: Intercept Pharmaceuticals vs. Gilead Sciences
Investing in biotech stocks might just be a great idea. The industry as a whole -- as measured by the SPDR S&P Biotech ETF Index -- provided a return of 45.5% over the past three years, narrowly outperforming the S&P 500 and its 44.5% return over the same period. Of course, there are scores of biotech companies to consider investing in, but let's turn our attention to two in particular: Intercept Pharmaceuticals (NASDAQ: ICPT) and Gilead Sciences (NASDAQ: GILD).
There are important differences between these two companies. For instance, Gilead Sciences' portfolio of products is diverse, whereas Intercept Pharma currently has only one product on the market. However, Intercept Pharma was the better performer last year: The company's shares grew by 22.95%, easily topping Gilead Sciences' 3.88% return. Will Intercept Pharma continue to outpace Gilead Sciences? Let's look at both companies' businesses and find out which is the better buy.
Image Source: Getty Images.
Source Fool.com
